| Literature DB >> 23219158 |
Mario Delgado-Ortega1, Daniel Marc, Joëlle Dupont, Sascha Trapp, Mustapha Berri, François Meurens.
Abstract
As for most biological processes, the immune response to microbial infections has to be tightly controlled to remain beneficial for the host. Inflammation is one of the major consequences of the host's immune response. For its orchestration, this process requires a fine-tuned interplay between interleukins, endothelial cells and various types of recruited immune cells. Suppressors of cytokine signalling (SOCS) proteins are crucially involved in the complex control of the inflammatory response through their actions on various signalling pathways including the JAK/STAT and NF-κB pathways. Due to their cytokine regulatory functions, they are frequent targets for exploitation by infectious agents trying to escape the host's immune response. This review article aims to summarize our current knowledge regarding SOCS family members in the different mammalian species studied so far, and to display their complex molecular interactions with microbial pathogens.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23219158 PMCID: PMC7112700 DOI: 10.1016/j.vetimm.2012.11.008
Source DB: PubMed Journal: Vet Immunol Immunopathol ISSN: 0165-2427 Impact factor: 2.046
Fig. 1(A) Structure of SOCS proteins. All SOCS proteins have (i) a central SH2 domain, (ii) an amino-terminal end domain of variable length including an extended SH2 sub-domain (ESS) and (iii) a carboxy-terminal SOCS box. SOCS1 and SOCS3 contain an additional amino-terminal kinase inhibitory region known as KIR. The SH2 domain of each SOCS determines its target-specificity, through binding phosphorylated (P) tyrosine residues that are specific to each substrate, such as JAK proteins. The SOCS box interacts with a complex containing elongin B, elongin C, cullin5, RING-box-2 (RBX2), and E2 ligase (also known as E2 ubiquitin-conjugating enzyme). This complex keeps the bound substrate close to the ubiquitinating machinery, thus facilitating its ubiquitination (U) and driving it towards proteosomal degradation. The KIR domain functions as a pseudosubstrate that inhibits the kinase activity of the SOCS-associated proteins. (B) Mechanism of suppression of the JAK/STAT pathway by SOCS1, SOCS3, and CIS. The cytokine or interferon stimulation of their cell surface receptors (1) activates receptor-associated JAK proteins by their phosphorylation (P). Then, activated JAKs phosphorylate receptor cytoplasmic domains (2). Recruited STATs are consequently activated by JAK phosphorylation (3). This phosphorylation enables their dimerization (4). Dimerized they can enter the nucleus and trigger as transcription factor complex the expression of various target genes including SOCS genes (5). Various SOCS proteins such as SOCS1, SOCS3 and CIS are produced (6). They can (7), as SOCS1 but also SOCS3, inhibit the JAK activity with their kinase inhibitory region. They can also, as SOCS3, compete with recruited STAT proteins for shared phosphotyrosine residues or specifically, as CIS, bind the phosphorylated tyrosine residues of cytokine receptors through the SH2 domain consequently masking the STAT5 docking site. Moreover, their SOCS box mediates ubiquitination and degradation of bound receptor components (8). Consecutively to their actions transcription factor complexes cannot anymore form and access the nucleus.
Fig. 2Overview of established and potential pathways targeted by SOCS proteins in a cell infected by HSV-1 and/or EBV. After HSV-1 infection and the stimulation of several pathogen recognition receptors (MDA5, RIG-1, TLR1/TLR2, TLR3, TLR7, TLR9), IFNβ is transcriptionally activated following the stimulation of various signalling pathways. SOCS proteins can act at different levels (inhibition of the JAK activity, competition with recruited STAT proteins for shared phosphotyrosine residues, phosphorylation of receptor tyrosine residues, ubiquitination and degradation of bound protein components) in the cell as indicated by stop signs. Question marks (?) indicate pathways that are possibly targeted by SOCS to modulate the anti-viral immune response. DDX3, Dead box protein 3; dsRNA, double stranded ribonucleic acid; EBV, Epstein-Barr Virus; HSV-1, Herpes Simplex Virus type 1; IFN, interferon; IKKα, I kappa-B kinase-alpha; IKKβ, I kappa-B kinase-beta; IKKi, kinase I kappa B kinase i; iNOS, inducible nitric oxide synthase; IRE, interferon response element; IRAK, IL1-Receptor-associated kinase; IRF, IFN-regulatory factor; JAK, janus kinase; MAVS, mitochondrial antiviral signalling protein; MDA5, melanoma differentiation-associated gene 5; MYD88, myeloid differentiation primary-response protein 88; NF-kβ, Nuclear factor kappa-B; P, phosphorylated tyrosine; p50, p50 subunit of NF-κB; TBK1, TANK-binding kinase 1; TRIF, TIR-containing adaptator inducing interferon-β;TLR, toll like receptor; TRAF, Tumor necrosis factor receptor (TNFR)-associated factor; RIG-1, Retinoic acid-inducible gene I; STAT, signal transduction and activators of transcription.
Fig. 3Alignments of CIS proteins from different mammalian and avian species. Consensus sequences are presented above and below the alignments. Below the bottom consensus sequence are indicated, in blue, the main regions of the CIS protein (SH2 and SOCS box). Alignments were performed using Emma and Showalign in the EMBOSS software suite.
Fig. 4Alignments of SOCS1 proteins from different mammalian and avian species. Consensus sequences are presented above and below the alignments. Below the bottom consensus sequence are listed, in blue, the main regions of the SOCS1 protein (Poly-Ser, KIR, ESS, SH2, SOCS box and the region interacting with Elongin BC complex). Alignments were performed using Emma and Showalign in the EMBOSS software suite.
Fig. 5Alignments of SOCS3 proteins from different mammalian and avian species. Consensus sequences are presented above and below the alignments. Above the top consensus sequence are mentioned the positions of α helix (green) and β sheets (purple). Below the bottom consensus sequence are listed, in blue, the main regions of the SOCS3 protein (KIR, ESS, SH2, and SOCS box). Alignments were performed using Emma and Showalign in the EMBOSS software suite. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article).
Microorganisms have developed multiple strategies to hijack the SOCS system in order to inhibit immune defense-signalling pathways.
| Microorganisms | SOCS proteins | Species involved | Functions |
|---|---|---|---|
| Bacteria | |||
| SOCS1 | Mouse | SOCS1 is induced by infection in a STAT1 and IFNα/β-dependent manner and may protect the host from inflammatory disease ( | |
| SOCS3 | Human | Decreases IFNγ production ( | |
| SOCS2/SOCS3 | Human | Inhibits JAK2 phosphorylation, alters p38-MAPK signalling ( | |
| SOCS1/SOCS3 | Human/mouse-cattle | Inhibits IL12 production by DCs, inhibits IFNγ signalling ( | |
| SOCS1 | Human | Increases levels of tyrosine kinase JAK2, hyperactivity of JAK/STAT ( | |
| SOCS2/SOCS3 | Human | Inhibits JAK2 phosphorylation, alters p38-MAPK signalling ( | |
| Protozoa | |||
| CIS/SOCS4 | Human | Regulates STAT3–STAT6 phosphorylation, down regulates miR-98 and | |
| SOCS2 | Pig | Potentially regulates IFNγ response ( | |
| SOCS3 | Human | Inhibits IFNγ signalling ( | |
| SOCS1 | Mouse | Inhibits IFNγ signalling ( | |
| CIS/SOCS1/SOCS3 | Mouse | Impairs macrophage activation by IFNγ, inhibits the up-regulation of MCH-II and ICAM1 and reduces iNOS induction, impairs IL12 production ( | |
| Virus | |||
| Coxsackievirus | SOCS1/SOCS3 | Human | Impairs IFNβ and IFNγ, impairs CT-1 signalling through gp130 receptor ( |
| EBV | SOCS1/SOCS3 | Human | Alters NF-κB signal cascade and p38-MAPK signalling ( |
| HBV | SOCS1/SOCS3 | Human | Suppression of STAT1, impairs IFNα signalling by suppression of STAT1 and blocking the TLR9/IRF-7 pathway ( |
| HCV | SOCS1/SOCS3/SOCS7 | Human | Regulates T and B cell functions, impairs production of IL12, inhibits phosphorylation and nuclear translocation of STAT1, degrades insulin receptor substrate 1 ( |
| HIV-1 | SOCS1/SOCS2/SOCS3 | Human | Impairs IFNγ signalling and IL12 production. Attenuates IFNβ signalling ( |
| HSV-1 | SOCS1/SOCS3 | Human/mouse | Inhibits IFNα, IFNβ, and IFNγ signalling ( |
| IAV | SOCS1/SOCS3 | Human/mouse/pig | Inhibits IFNα and IFNβ signalling through RIG-1/MAVS/IFNAR1 pathway ( |
| MuHV-4 | Viral SOCS-box (ORF73) | Mouse | Inhibition of NF-κB pathway ( |
| PRRSV | SOCS1 | Pig | Potentially regulates IFNγ response ( |
| RSV | CIS/SOCS1/SOCS3 | Human | Impairs type I and type II IFNs inhibiting STAT1 and STAT2 phosphorylation ( |
| SARS Co-V | SOCS3 | Human | Enhancement of IL6 signalling by a lower induction of SOCS3 and dysfunction of STAT3 ( |
| TBEV | SOCS1/SOCS3 | Mouse | Potentially limits cytokine response ( |
| WNV | SOCS1/SOCS3 | Mouse | Potentially limits cytokine response ( |